A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

FDA Gives Emergency Use Authorization to Two Drugs to Fight COVID-19


The US Food and Drug Administration has given two drugs—hydroxychloroquine sulfate and chloroquine phosphate—Emergency Use Authorization for the treatment of hospitalized patients with COVID-19. Announced on Sunday, March 29, the declaration enabled donations of the drugs to be made to the Strategic National Stockpile (SNS), which then distributes the medications to hospitals. The SNS has since received 30 million doses of hydroxychloroquine from Sandoz and 1 million doses of chloroquine phosphate from Bayer Pharmacueticals. While no clinical trials have been conducted yet, anecdotal evidence suggests the drugs, typically used to treat malaria and other diseases, show activity against SARS-CoV-2, the virus that causes COVID-19. Read more here.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy